Newsletter | August 27, 2019

08.27.19 -- Gene Delivery Tech That Creates Cell Therapies


Here’s your Tuesday line-up, Cell & Gene readers:


As more cell-based therapies transition toward the market, hurdles surrounding safety, efficacy, and manufacturing are becoming increasingly apparent. The advancement of gene delivery technologies is fundamental to driving more clinical prospects of cell therapies. Here’s how gene delivery technologies are creating tomorrow’s cell therapies.


Renovacor recently announced the successful completion of an $11 million Series A financing co-led by Novartis Venture Fund, Broadview Ventures, and BioAdvance, and joined by New Leaf Venture Partners and Innogest Capital. There are currently no precision medicine options for cardiovascular patients with specific genetic mutations — a deficiency that Renovacor hopes to address. I talked to Dr. Maggie Cook, president and CEO of Renovacor about how the company plans to address this deficiency and to determine what patients with DCM can expect if the gene therapy development is successful.


Erin Harris, editor in chief
Follow me on Twitter

Industry Insights
Cell Therapy Manufacturing: The Supply Chain Challenge
Article | By Christina Bennett, GE Healthcare Life Sciences

Overcoming the challenges of manufacturing and administering a complex product to any patient is critical for delivering cell therapies. Two industry experts detail strategies to meet supply chain challenges.

Considering Options And Alternatives For The Design Of Complex Biopharma Facilities
White Paper | By Tom Piombino and Sue Behrens, Integrated Project Services (IPS)

The movement of viral vectors, cell therapies, and other antibody-based next-generation drug products toward commercialization is driving the need for new and different technologies and facilities. Engineering and design firms with the right skill sets can help you maintain the right balance in your facility design to maintain flexibility, which is essential to meet diverse processing needs for biopharmaceutical manufacturing.

Implementing Global Best Practices For Single-Use Systems
Case Study | CPC

Single-use technology has only been used at manufacturing scale for about 10 years. Relative to other technologies, single-use systems are new and experience can be limited. 

Cell Processing Overview
GE Healthcare Life Sciences
Connect With Cell & Gene: